LENZ Therapeutics (LENZ) Depreciation & Amortization (CF) (2020 - 2026)
LENZ Therapeutics (LENZ) reported Depreciation & Amortization (CF) of $111000.0 for Q1 2026, up 208.33% year-over-year from $36000.0 in Q1 2025, and up 3.74% on a QoQ basis from $107000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $111000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 208.33% year-over-year to $111000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $362000.0 (up 306.74% YoY) and the FY2025 annual result came in at $287000.0, up 394.83% from the prior year.
- Depreciation & Amortization (CF) climbed to $111000.0 in Q1 2026 per LENZ's latest filing, from $107000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $682000.0 in Q4 2022 and bottomed at $3000.0 in Q1 2023.
- The 5-year median for Depreciation & Amortization (CF) is $25000.0 (2024), against an average of $166058.8.
- The widest annual swing landed in 2023, when Depreciation & Amortization (CF) plunged 99.41%; it then soared 1150.0% in 2025.
- Tracing LENZ's Depreciation & Amortization (CF) over 5 years: stood at $682000.0 in 2022, then sank by 99.41% to $4000.0 in 2023, then jumped by 525.0% to $25000.0 in 2024, then soared by 328.0% to $107000.0 in 2025, then gained by 3.74% to $111000.0 in 2026.
- Per Business Quant, the three latest LENZ Depreciation & Amortization (CF) figures stand at $111000.0 (Q1 2026), $107000.0 (Q4 2025), and $125000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 111,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 111,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 3,000.00 |
| Mar 31, 2023 | 3,000.00 |
| Dec 31, 2022 | 682,000.00 |
| Dec 31, 2022 | 682,000.00 |
| Sep 30, 2022 | 652,000.00 |
| Sep 30, 2022 | 652,000.00 |
| Jun 30, 2022 | 578,000.00 |
| Jun 30, 2022 | 578,000.00 |
| Mar 31, 2022 | 440,000.00 |
| Mar 31, 2022 | 440,000.00 |
| Dec 31, 2021 | 330,000.00 |
| Dec 31, 2021 | 330,000.00 |
| Sep 30, 2021 | 198,000.00 |
| Sep 30, 2021 | 198,000.00 |
| Jun 30, 2021 | 116,000.00 |
| Jun 30, 2021 | 116,000.00 |
| Mar 31, 2021 | 90,000.00 |
| Mar 31, 2021 | 90,000.00 |
| Dec 31, 2020 | 76,000.00 |
| Dec 31, 2020 | 76,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |